Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.

Bharat Biotech International Ltd. engages in research and development, manufacturing, marketing and distribution of vaccines and biotherapeutics. It focuses on the development of novel health care solutions for region-specific neglected diseases. The firm offers Revac-B+, REGEN-D, HNVAC, COMVAC5, BIOPOLIO, INDIRAB, Typbar TCV, BIOHIB, JENVAC, ROTAVAC and vaccine candidates against chikungunya, chandipura, HPV and Ebola. The company was founded by Krishna Murthy Ella and Suchitra K. Ella in 1996 and is headquartered in Hyderabad, India..

VLife provides high performance, accurate and reliable solutions for improving productivity in drug and molecular discovery. VLife's products are benchmarked as 'Best in Class' for a wide spectrum of critical research objectives and functionalities. VLife products ensure that researchers get 'All applications for a specific domain in one product'. If a researcher is focused on: 1.QSAR only, all they have to license in is the QSARProâ„¢ 2.Protein modeling and Docking, BioPredictaâ„¢ is all one needs 3.Cheminformatics, then product of choice is ChemXplorâ„¢ 4.If the scientists' interest is across CADD workspace, they can license VLifeMDSâ„¢; the comprehensive flagship product of VLife

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. They have four approved products on the market today and they are not stopping there! From the United States to Europe to the Asia Pacific, they are proud of their multicultural business environment where employees can collaborate with people all over the world. As a group, they are relentless in their pursuit of “medicines for life”® and continue their research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.

Founded in 1995, Indus Biotech is a pioneer in deriving science based dietary ingredients from food chain raw materials through revolutionary patented technology. Their products are subjected to the highest levels of scientific rigour. We understand the mechanism of action and the chemistry and manufacturing control of our products. This leads to standardization and reproducibility in our manufacturing process.

Fidia Farmaceutici SpA manufactures pharmaceutical products. The firm's platform technology level is the chemical modification, development, and manufacturing of state-of-the-art pharmaceuticals and medical devices based on hyaluronan covering therapeutic categories. The company was founded in 1946 and is headquartered in Abano Terme, Italy.

Foshan Youte Medical Technology Co., Ltd., established on 2010-12-17, Business scope includes medical,Manufacturing of surgical and veterinary instruments;medical diagnosis,Monitoring and treatment equipment manufacturing;Manufacturing of medical laboratories and medical disinfection equipment and appliances;Manufacture of Mechanical Therapy and Ward Nursing Equipment;Other medical equipment and equipment manufacturing;Sanitary materials and medical supplies manufacturing;Pharmaceutical excipients and packaging materials;Bio-based chemical fiber manufacturing;Manufacturing of chemical preparations;Cosmetic Manufacturing;Medical supplies and equipment retail;Wholesale of medical supplies and equipment;Technology intermediary service;Wholesale of cosmetics and hygiene products;Retailing of cosmetics and hygiene products;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(The above projects do not involve special management measures for foreign investment access)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.

ArthroCare develops and manufactures surgical devices, instruments, and implants that strive to enhance surgical techniques as well as improve patient outcomes. Its devices improve many existing surgical procedures and enable new minimally invasive procedures. Many of ArthroCare's devices use its internationally patented Coblation (R) technology. This technology precisely dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology including its OPUS (R) line of fixation products as well as re-usable surgical instruments. ArthroCare is leveraging these technologies in order to offer a comprehensive line of surgical devices to capitalize on a multi-billion dollar market opportunity across several surgical specialties, including its two core product areas consisting of Sports Medicine and Ear, Nose, and Throat as well as other areas such as spine, wound care, urology and gynecology.

Xylos Corporation, a biomaterials-based medical device company, provides biomaterial solutions for the treatment, repair, and replacement of human tissues. The company focuses on the development of select surgical implants for the musculoskeletal field. It solutions include biocellulose technology that delivers a biomaterial for medical devices to address a range of medical applications, including surgical implants for musculoskeletal, urological/gynecological, general, abdominal, cardiovascular, and plastic/aesthetics indications. The company also provides its technology solution for regenerative, neurosurgery, chronic wound care, cardiothoracic surgery, drug and active compound delivery, uro-gynecological surgery, spinal surgery, oral and cranio-maxillofacial surgery, plastic and reconstructive surgery, and regenerative medicine applications. Xylos Corporation was founded in 1996 and is based in Langhorne, Pennsylvania.

BSN Medical, Inc. manufactures and supplies medical equipment. Its brands include Actimove, Comprilan, Delta-Lite, Specialist and Tensoplast. The company is headquartered in Charlotte, NC.

Bruin Biometrics, LLC (“BBI”) is a multi-member partnership formed in 2009 and has exclusively licensed wireless health technologies from the UCLA Wireless Health Institute. BBI’s mission is to develop a robust portfolio of patent-protected, FDA-approved wireless health devices targeting significant medical conditions and unmet medical needs. The lead product under development is the Sub-Epidermal Moisture (“SEM”) Scanner Device used to detect pressure ulcers.

Part of Smith & Nephew plc, T.J. Smith & Nephew Ltd. is a British company located in Hull that manufactures healthcare products. It was founded in 1907. On July 01, 1999 Robinson Healthcare Group Ltd. acquired T.J. Smith & Nephew Ltd. from Smith & Nephew plc for $22.60 million.\nThe company says this about itself: The principal activity of the company is he design. development manufacture and sale of Advanced medical devices.

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

The USC Incubator accelerates the development of USC’s top student and alumni entrepreneurs through experiential education, mentorship and community. The USC Incubator, supported by the Greif Center for Entrepreneurial Studies at USC’s Marshall School takes founders from feasibility and development work, on to customers, a tested business model, getting distribution, building a team, bootstrapping and investment preparation. They also provide access to other supporting resources, such as legal and financial assistance.

Develops, produces and distributes medical and hygiene products

Under the corporate philosophy of "Value Creation with Respect for Man's Life and Dignity", IL-YANG PHARM was established in 1946 and stepped forward with the growth of Korean pharmaceutical industry. Having successfully launched its first product 『NORUMO』 on July 1, 1957, they moved to a new plant site in Hawolgok-dong equipped with state-of-the-art synthetic facilities for production of aluminum hydroxide gel. Entering the 1960's, they quickly expanded under management modernization with new product development and sought multilateral changeover in management in the 19R70's. Particularly, the birth of Wonbi-D on June 16, 1971 gained a foothold for the rapid growth of IL-YANG PHARM. After founding Neusiline composition plant in Yongin in November 1972, they went through business opening in 1742 and became the 125th listed company in Korea.